Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 5/20 | 0.43 |
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.43 |
| ▸ | CA12 known ✓ | O43570 | 4/20 | 0.43 |
| ▸ | PDK2 known ✓ | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 known ✓ | Q16654 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Ion SCHEMBL11175859 | 0.96 | HSD17B1 (0.50) | HSD17B1HSP90AB1CA1CA2CA12 | |
| Potassium Ion SCHEMBL1012149 | 0.96 | HSD17B1 (0.50) | HSD17B1HSP90AB1CA1CA2CA12 | |
| SCHEMBL3873140 | 0.93 | CA1 (0.47) | HSD17B1HSP90AB1CA1CA2CA12 | |
| SCHEMBL137806 | 0.87 | HSD17B3 (0.45) | HSD17B1HSP90AB1CA1CA2CA12 | |
| Water SCHEMBL8361961 | 0.86 | HSD17B3 (0.44) | HSD17B1HSP90AB1CA1CA2CA12 | |
| SCHEMBL2325181 | 0.84 | TYR (0.53) | HSP90AB1CA1CA2CA12CA7 | |
| SCHEMBL344000 | 0.84 | TYR (0.53) | HSP90AB1CA1CA2CA12CA7 | |
| Ethylparaben SCHEMBL3873139 | 0.84 | CA12 (0.62) | CA1CA2CA12CA7CA9 | |
| Potassium Ion SCHEMBL851715 | 0.84 | HSD17B3 (0.45) | HSD17B1HSP90AB1CA1CA2CA12 | |
| Zinc Ion SCHEMBL11170436 | 0.84 | HSD17B3 (0.45) | HSD17B1HSP90AB1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 956 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120983376-B | Clofazimine soft capsule and preparation method thereof | SHANXI LIYE PHARMACEUTICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| EP-4743053-A1 | ANTIMICROBIAL SYNERGIES | Symrise AG (DE) | 2026-05-20 | — | — | EP | claimed |
| CN-119905535-B | Olivine sodium iron phosphate composite material and preparation method and application thereof | 四川易纳能新能源科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026088186-A1 | FERMENTED AND DEHYDRATED ALOE GEL PRODUCT AND PROCESS FOR THE PREPARATION THEREOF | YOSHAY IDO MOSHE (IL) | 2026-04-30 | — | — | WO | claimed |
| EP-4554551-B1 | 3-HYDROXYPROPYLESTERS AS ANTIMICROBIAL AGENTS | SYMRISE AG (DE) | 2026-03-11 | — | — | EP | claimed |
| EP-3843703-B1 | PARACETAMOL LIQUID SUSPENSIONS | HALEON CH SARL (CH) | 2025-11-05 | — | — | EP | claimed |
| US-20250281426-A1 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | Yichang Humanwell Pharmaceutical Co., Ltd. (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4608929-A1 | BRIDGING PARTICLE AND FLUID LOSS CONTROL AGENT | LyondellBasell Advanced Polymers Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-12338390-B2 | Bridging particle and fluid loss control agent | LYONDELLBASELL ADVANCED POLYMERS INC. (US) | 2025-06-24 | — | — | US | claimed |
| EP-4554551-A1 | 3-HYDROXYPROPYLESTERS AS ANTIMICROBIAL AGENTS | Symrise AG (DE) | 2025-05-21 | — | — | EP | claimed |
| EP-2091892-A2 | CALCIUM FORMIATE FERTILISER | Lanxess Deutschland GmbH (DE) | 2009-08-26 | — | — | EP | claimed |
| US-20080312195-A1 | Preservatives | CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) | 2008-12-18 | — | — | US | claimed |
| WO-2008058936-A2 | CALCIUM FORMIATE FERTILISER | LANXESS DEUTSCHLAND GMBH (DE) | 2008-05-22 | — | — | WO | claimed |
| EP-1845934-B1 | PRESERVATIVES | CLARIANT PRODUKTE DEUTSCHLAND (DE) | 2008-05-14 | — | — | EP | claimed |
| EP-1793925-A2 | IMPREGNATED FILTER ELEMENTS, AND METHODS | DONALDSON COMPANY, INC. (US) | 2007-06-13 | — | — | EP | claimed |
| EP-1452169-B1 | AQUEOUS BASE LIQUID PHARMACEUTICAL COMPOSITIONS IN SUSPENSION FORM FOR THE ORAL ADMINISTRATION OF IBUPROFEN | FARMALIDER SA (ES) | 2007-01-24 | — | — | EP | claimed |
| US-7128923-B2 | Preserved and stable compositions containing peptide copper complexes and method related thereto | PROCYTE CORPORATION (US) | 2006-10-31 | — | — | US | claimed |
| WO-2006026517-A2 | IMPREGNATED FILTER ELEMENTS, AND METHODS | DONALDSON COMPANY, INC. (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060042210-A1 | Acidic impregnated filter element, and methods | DONALDSON COMPANY, INC. | 2006-03-02 | — | — | US | claimed |
| EP-1452169-A1 | AQUEOUS BASE LIQUID PHARMACEUTICAL COMPOSITIONS IN SUSPENSION FORM FOR THE ORAL ADMINISTRATION OF IBUPROFEN | Farmalider, S.A. (ES) | 2004-09-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281426-A1 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | GRIK5, GRIK1, GRIK3 | CA1 3689/4885CA2 3754/4885CA12 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.